Side Effects of Lynparza, Rubraca, Similar Cancer Drugs May Increase Risk Of Leukemia: Study

The findings of a new study suggests the side effects of Lynparza, Rubraca and similar poly-ADP ribose polymerase (PARP) inhibitors may increase the risk of some types of blood cancer.

In a report published in The Lancet Haematology on December 18, French researchers found an association between PARP inhibitors and an increased risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

The drugs are used in a number of cancer treatments; ovarian cancer in particular. However, the researchers indicate there have long been concerns of their potential link to cancers of the blood.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In the study, researchers reviewed a number of randomized controlled clinical trials which compared PARP inhibitor therapy with placebos and other cancer drugs treated for cancer. Ultimately, they looked at data from 5,693 patients who took drugs like Lynparza and Rubraca, as well as 3,406 patients in control groups.

According to their findings, PARP inhibitors use more than doubled the risk of cancer when compared to patients who were given a placebo. Incidence of either cancer in PARP inhibitor patients was 0.73%, compared with only 0.47% among the control subjects.

In the 104 cases linked to MDS or AML diagnoses, 47, or 45%, of the patients died. The median treatment duration was 9.8 months and the latency period before cancer was detected was 17.8 months from first PARP inhibitor exposure.

“PARP inhibitors increased the risk of myelodysplastic syndrome and acute myeloid leukemia versus placebo treatment,” the researchers concluded. “These delayed and often lethal adverse events should be studied further to improve clinical understanding, particularly in front-line maintenance setting.”

The researchers noted that the association to ovarian cancer in particular may be because clinical trials involving this form of cancer generally had a longer follow-up than other types of cancer.

1 Comments

  • LindaAugust 1, 2022 at 8:58 pm

    This made my husband really sick what can I do

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.